Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 9038-9049
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9038
Table 1 Summary of the major findings obtained among the most widespread in vivo models
ModelGenetic manipulationDiet modificationsObesityMetabolic syndrome (IR)HepatosteatosisSteatohepatitisFibrosis
ob/obLeptin DeficientNoYesYesYesYes (in males)No (protected)
miceYesVariableYesYesYesYes
MCD(loss weight in some)
db/dbMutation on leptin receptorNoYesYesYesNoNo
miceYesVariableNoYesYesYes
MCD(age-related weight gain)
AOXNullizygous for acycil - CoA oxidaseNoNoNoYesYesNo
null mice[before 6-8 mo(before 6-8 mo)
ResistantResistant
(after 8 mo)](after 8 mo)
MATONullizygous for (MAT)-1ANoNoNoYesYesYes
null mice
ptenLiver specific pten deletionNoNoNoYesYesYes
null mice
(SREBP)-1cSREBP-1c overexpressed in adipose tissueNoNoYesYesYesYes
transgenic mice
KK-AyHeterozygous mutation on agouti gene (KK-Ay/a)NoYesYesYesNoNo
miceYesYesYesYesYesNo
MCD
LIRKOLiver-specific Leptin receptor KONoNoHepatic IRNo--
mice
C57Bl/6JNoYesYesYesYesYesYes
HFHC(mild)
HF
Cholesterol-CholateNoYesNoNoYesYesYes
(Atherogenic diet)Cholesterol(only hepatic IR)(over 1-6 mo)(over 1-6 mo)(over 1-6 mo)
Cholate